Effect of nicorandil on the quality of life and course of the disease in patients with heart failure in ischemic heart disease
- Authors: Makarovskaya V.V.1, Ryazanov A.S2, Kudryavtsev A.A2, Kapitonov K.I1
-
Affiliations:
- Clinical and Diagnostic Center №4 of the Moscow City Health Department
- I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 20, No 10 (2018)
- Pages: 47-52
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95080
- DOI: https://doi.org/10.26442/2075-1753_2018.10.47-52
- ID: 95080
Cite item
Full Text
Abstract
Objective: to assess the effect of nicorandil on the quality of life and on the long-term outcomes in patients with cardiac insufficiency of ischemic etiology. Materials and methods. The evidence base of nicorandil is analyzed. In a long-term out-patient observation, 175 people with a combination of coronary heart disease and heart failure, who were additionally assigned to nicorandil, were included in the Clinic-Diagnostic Center №4 in Moscow. They determined the incidence of anginal attacks, changes in the functional class of heart failure, and changes in the quality of life. Results. The follow-up was 13 months. The number of patients with I functional class increased by 45%, with III functional class decreased by 38%. In 71% of patients, the need for short-acting nitrates decreased. The connection between the reception of nicorandil and the improvement of the quality of life was revealed, and the tolerance to loads was increased. The degree of adherence to treatment was studied. Conclusion: the additional use of nicorandil to the main antianginal therapy improves the quality of life of patients with heart failure and coronary heart disease and has a positive effect on long-term outcomes.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
V. Vladimirovna Makarovskaya
Clinical and Diagnostic Center №4 of the Moscow City Health Department
Email: marja.makarovska@mail.ru
врач отд-ния функциональной диагностики 121609, Russian Federation, Moscow, ul. Krylatskie kholmy, d. 3
A. S Ryazanov
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federationпроф., ИПО каф. общей врачебной практики 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
A. A Kudryavtsev
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federationассистент, ИПО каф. общей врачебной практики 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
K. I Kapitonov
Clinical and Diagnostic Center №4 of the Moscow City Health Departmentканд. мед. наук, зав. отд-нием функциональной диагностики 121609, Russian Federation, Moscow, ul. Krylatskie kholmy, d. 3
References
- Болезни сердца по Браунвальду. Т. 3. М.: Логосфера, 2013
- Верткин Ф.Л., Кнорринг Г.Ю. За рамками инвазивной кардиологии. Consilium Medicum. 2016; 18 (10): 43-8.
- IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet 2002; 359 (9314): 1269-75.
- Ешихиса А., Сато Ю., Ватанабе С. и др. Снижение смертности у больных с сердечной недостаточностью ишемической этиологии, принимающих никорандил. Consilium Medicum. 2017; 19 (10): 74-8. doi: 10.26442/2075-1753_19.10.74-78
- Task Force, Montalescot G, Sechtem U et al. 2013 ESC guidelineson the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949-3003.
- Zhu W.L et al. Double-blind, multicenter, active controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J 2007; 71 (6): 826-33.
- Japanese Coronary Artery Disease (JCAD) Study Investigators. Current status of the background of patients with coronary artery disease in Japan. Circ J 2006; 70 (10): 1269-75.
- Воронина В.П., Марцевич С.Ю., Кутишенко Н.П. и др. Оценка антиишемического и антиангинального эффектов никорандила с помощью нагрузочных тестов на тредмиле в рамках исследования КВАЗАР. Рос. кардиол. журн. 2017; 2 (149): 91-7.
- Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П. и др. Наблюдательное многоцентровое исследование применения никорандила у больных стабильной ишемической болезнью сердца с высоким сердечно-сосудистым риском (НИКЕЯ): дизайн, первые результаты. Рос. кардиол. журн. 2017; 9 (149): 75-82.
- ВНОК. Рациональная фармакотерапия больных ССЗ. Российские рекомендации. Кардиоваскулярная терапия и профилактика. 2009; 8 (6; Прил. 4): 12.
- Luo B, Wu P, Bu T et al. All-cause mortality and cardiovascular events with nicorandil in patients with IHD: systematic review and metaanalysis of the literature. Int J Cardiol 2014; 176 (3): 661-9.
- Рябихин Е.А., Можейко М.Е., Красильников Ю.А. и др. Дополнительные возможности в лечении ишемической болезни сердца, осложненной хронической сердечной недостаточностью с низкой фракцией выброса левого желудочка. Сердечная недостаточность. 2016; 17 (1): 3-9.
